TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02513485

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levodopa+carbidopa
Description: Sinemet is a combination of 250 mg levodopa and 50 mg carbidopa. Sinemet will be administered orally at Visit 1 or Visit 2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levodopa+carbidopa
Description: Sinemet is a combination of 250 mg levodopa and 50 mg carbidopa. Sinemet will be administered orally at Visit 1 or Visit 2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: A placebo is a sugar pill that has no therapeutic effect and will be administered orally at Visit 1 or Visit 2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: A placebo is a sugar pill that has no therapeutic effect and will be administered orally at Visit 1 or Visit 2.
Study: NCT04363255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide Injection
Description: Etoposide(100mg/m2, d1-3, q3w) combined with platinum was the first-line chemotherapy in 4-6 cycles, and then JS001 combined with anlotinib as maintenance therapy were followed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin Injection
Description: Carboplatin(AUC 5, d1, q3w) or Cisplatin combined with etoposide was the first-line chemotherapy in 4-6 cycles, and then JS001 combined with anlotinib as maintenance therapy were followed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin injection
Description: Cisplatin(75mg/m2, d1, q3w) or carboplatin combined with etoposide was the first-line chemotherapy in 4-6 cycles, and then JS001 combined with anlotinib as maintenance therapy were followed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: After 4-6 cycles of chemotherapy, JS001(240mg, d1, q3w) combined with anlotinib were followed and continued until disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib hydrochloride
Description: After 4-6 cycles of chemotherapy, anlotinib(12mg qd, d1-14, q3w) combined with JS001 were followed and continued until disease progression.
Study: NCT05171595

Intervention type: DEVICE
Intervention: Lifetouch single-lead ECG monitoring
Description: The continuous wireless monitoring is a single-lead ECG patch (Isansys Life Touch patch) which consists of two ECG electrodes placed on the left side of the patients' thorax. The patch measures respiratory rate (RR), heart rate (HR), heart rate variability (HRV) and electrocardiogram (ECG)s.

Intervention type: DEVICE
Intervention: Lifetouch single-lead ECG monitoring
Description: The continuous wireless monitoring is a single-lead ECG patch (Isansys Life Touch patch) which consists of two ECG electrodes placed on the left side of the patients' thorax. The patch measures respiratory rate (RR), heart rate (HR), heart rate variability (HRV) and electrocardiogram (ECG)s.

Intervention type: DIAGNOSTIC_TEST
Intervention: high-sensitive TnT measurements
Description: Another monitoring device in the study was the plasma concentration of high-sensitive cardiac troponin T (hsTnT).
Study: NCT04047862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered in accordance with local guidelines , prescribing information/summary of product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Administered in accordance with local guidelines , prescribing information/summary of product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered in accordance with local guidelines , prescribing information/summary of product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered in accordance with local guidelines , prescribing information/summary of product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered in accordance with local guidelines , prescribing information/summary of product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered in accordance with local guidelines , prescribing information/summary of product
Study: NCT05171595

Intervention type: DIAGNOSTIC_TEST
Intervention: high-sensitive TnT measurements
Description: Another monitoring device in the study was the plasma concentration of high-sensitive cardiac troponin T (hsTnT).
Study: NCT04359550

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant human anti-PD-L1 monoclonal antibody (ZKAB001)
Description: Recombinant human anti-PD-L1 monoclonal antibody (ZKAB001)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT01008007

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Viusid
Description: One Viusid bag (4 grams, orally administered) every 8 hours, for 6 days in combination with the conventional treatment consisting in: intramuscular injection of one bulb of Dipyrone (600 mg) every 8 hours if fever is greater or equal to 38 ºC; intramuscular injection of one bulb of dimenhydrinate (50 mg) every 8 hours if vomiting; oral rehydration solution (8 ounce) after each diarrhea.
Study: NCT03604991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study: NCT01008007

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: Conventional treatment consisting in: intramuscular injection of one bulb of Dipyrone (600 mg) every 8 hours if fever is greater or equal to 38 ºC; intramuscular injection of one bulb of dimenhydrinate (50 mg) every 8 hours if vomiting; oral rehydration solution (8 ounce) after each diarrhea.
Study: NCT00867009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Induction therapy: 500 mg/m², intravenous, on Day 1 of each 21-day cycle for 4 to 6 cycles Maintenance therapy: 500 mg/m², intravenous, on Day 1 of each 21-day cycle until progressive disease or treatment discontinuation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Induction therapy: 75 mg/m², intravenous, on Day 1 of each 21-day cycle for 4 to 6 cycles
Study: NCT04047862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered in accordance with local guidelines , prescribing information/summary of product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered in accordance with local guidelines , prescribing information/summary of product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered in accordance with local guidelines , prescribing information/summary of product
Study: NCT00867009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Induction therapy: Loading dose of 400 mg/m², intravenous, on Day 1 of cycle 1, then 250 mg/m², intravenous, weekly for 4 to 6 cycles, 21 day cycles~Maintenance therapy: 250 mg/m², intravenous, weekly until progressive disease or treatment discontinuation
Study: NCT00705653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PG-11047
Description: PG-11047 will be administered as a 60-minute intravenous infusion on days 1, 8 and 15 of each 28 day cycle. A treatment cycle will be defined as 4 weeks of therapy. The planned minimum treatment schedule is 2 cycles of PG-11047 treatment (8 weeks).
Study: NCT03383172

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: I Can Problem Solve (ICPS) Program
Description: The 59 sessions of ICPS program explicitly promote cognitive regulation, solving social problems, and emotional learning skills.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: I Can Problem Solve (ICPS) Program
Description: The 59 sessions of ICPS program explicitly promote cognitive regulation, solving social problems, and emotional learning skills.
Study: NCT01803919

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silver Alloy-Coated Urinary Catheters

Intervention type: DEVICE
Group type: OTHER
Intervention: Conventional Urinary Catheter
Study: NCT03992859

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous serratus plane block
Description: Peripheral nerve catheter placed by the surgeon at the end of surgery
Study: NCT02059486

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teen Choice
Description: The curriculum provides sexual education on topics such as anatomy, puberty, sexually transmitted infections, and contraceptive methods (including abstinence). It also covers topics such as gender and sex roles, sexual orientation, decision making and conflict resolution, adult-teen relationships, rape and sexual assault, and coping with stress.
Study: NCT01133483

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fexofenadine HCl + Pseudoephedrine HCl
Description: Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tablets of Dr. Reddy's Laboratories Limited

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl + Pseudoephedrine HCl
Description: Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tablets of Dr. Reddy's Laboratories Limited
Study: NCT02547454

Intervention type: DRUG
Intervention: Methoxy polyethylene glycol-epoetin beta
Study: NCT00147199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled treprostinil
Description: Doses are titrated to 9 breaths four times daily. Each breath produces an 18 mcg dose of inhaled treprostinil.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo inhalation solution
Description: Doses are titrated to 9 breaths four times daily.
Study: NCT00580606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycerinated peanut allergenic extract
Description: Glycerinated peanut extract delivered sublingually.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for peanut extract (glycerin)
Description: Placebo (glycerin) delivered sublingually.
Study: NCT03066271

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise +
Description: Usual care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control +
Description: Usual care
Study: NCT02980445

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Outdoor activity 1
Description: 40-minute outdoor activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Outdoor activity 2
Description: Dose 1 plus an additional 40-minute outdoor activities during recesses
Study: NCT04047862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered in accordance with local guidelines , prescribing information/summary of product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Administered in accordance with local guidelines , prescribing information/summary of product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5fluorouracil
Description: Administered in accordance with local guidelines , prescribing information/summary of product
Study: NCT03604991

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET scan
Study: NCT04047862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5fluorouracil
Description: Administered in accordance with local guidelines , prescribing information/summary of product
Study: NCT00240162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTK787/ZK 222584
Study: NCT03604991

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study: NCT04047862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5fluorouracil
Description: Administered in accordance with local guidelines , prescribing information/summary of product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Administered in accordance with local guidelines , prescribing information/summary of product
Study: NCT00788476

Intervention type: OTHER
Intervention: Survey
Description: Survey packets to adult (\>18 years old) childhood cancer survivors who return to MDACC for follow-up appointments within the next 12-months and conduct a mailed survey with the remaining participants and their primary caregivers i.e. guardians of survivors who are currently under age 18.

Intervention type: OTHER
Intervention: Survey
Description: Survey packets to adult (\>18 years old) childhood cancer survivors who return to MDACC for follow-up appointments within the next 12-months and conduct a mailed survey with the remaining participants and their primary caregivers i.e. guardians of survivors who are currently under age 18.
Study: NCT02401815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX9486
Description: PLX9486 will be administered per dose and schedule specified in the arm.
Study: NCT04047862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Administered in accordance with local guidelines , prescribing information/summary of product
Study: NCT03888404

Intervention type: OTHER
Intervention: Pregnancy preferences (Aim 1)
Description: The primary exposure of interest for Aim 1 will be pregnancy preferences, measured with the Desire to Avoid Pregnancy scale.

Intervention type: OTHER
Intervention: Sociocultural environment (Aim 2)
Description: For Aim 2 will assess the roles of contextual and individual variables on pregnancy decision-making and care-seeking outcomes (including state political environment, stigma, social emotional and instrumental support, feelings about the pregnancy, SES).
Study: NCT02401815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX9486
Description: PLX9486 will be administered per dose and schedule specified in the arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX9486
Description: PLX9486 will be administered per dose and schedule specified in the arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX9486
Description: PLX9486 will be administered per dose and schedule specified in the arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX9486
Description: PLX9486 will be administered per dose and schedule specified in the arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX9486
Description: PLX9486 will be administered per dose and schedule specified in the arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX9486
Description: PLX9486 will be administered per dose and schedule specified in the arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX9486
Description: PLX9486 will be administered per dose and schedule specified in the arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX9486
Description: PLX9486 will be administered per dose and schedule specified in the arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX9486
Description: PLX9486 will be administered per dose and schedule specified in the arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pexidartinib
Description: Pexidartinib capsules will be administered per dose and schedule specified in the arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pexidartinib
Description: Pexidartinib capsules will be administered per dose and schedule specified in the arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Sunitinib will be administered per dose and schedule specified in the arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Sunitinib will be administered per dose and schedule specified in the arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Sunitinib will be administered per dose and schedule specified in the arm.
Study: NCT04575922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Administered into vein by intravenous infusion every 2 weeks over 6 week study cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Administered into vein by intravenous infusion day 1 of each 6 week study cycle.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: 3 radiation treatments, every other weekday or 2 days during week 1 of cycle 1 only of study.
Study: NCT02846779

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low intensity
Description: Low intensity telepharmacy outreach

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate intensity
Description: Moderate intensity telepharmacy outreach

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity
Description: High intensity telepharmacy outreach
Study: NCT00260351

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Purified Verocell Rabies Vaccine
Description: 0.1 mL, ID (TRC regimen)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Purified Verocell Rabies Vaccine
Description: 0.5 mL, IM (ZAGREB regimen)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Purified Verocell Rabies Vaccine
Description: 0.5 mL, IM (ESSEN regimen)
Study: NCT00531999

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raltegravir then lopinavir/ritonavir
Description: raltegravir 400mg twice daily for first 14 days of study lopinavir/ritonavir 400/100mg twice daily for last 14 days of study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir/ritonavir then raltegravir
Description: lopinavir/ritonavir 400 mg twice daily for the first 14 days of the study raltegravir 400mg twice daily for the last 14 days of the study
Study: NCT01880385

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: During neoadjuvant phase: 15 mg/kg, d1 q3w, 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Neoadjuvant: 500 mg/m2 d1 q3w, 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin hydrochloride
Description: Neoadjuvant: 100 mg/m2, d1 q3w, 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Neoadjuvant: 500 mg/m2, d1 q3w, 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Adjuvant: 100 mg/m2 q3w, 4 cycles

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Adjuvant: 8 mg/kg d1 in the 1st cycle then 6 mg/kg for d1 q3w, 17 cycles if tumor overexpress HER2
Study: NCT03176251

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gamified-Integrated Curriculum
Description: The experimental group will receive identical training compared to the control group, with the additional incorporation of several elements of gamification, as outlined in the Arm/Group descriptions.
Study: NCT03176251

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gamified-Integrated Curriculum
Description: The experimental group will receive identical training compared to the control group, with the additional incorporation of several elements of gamification, as outlined in the Arm/Group descriptions.
Study: NCT00864214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bioidentical hormone (Biest)
Description: Estrogen is the Biest 2.0 mg bioidentical cream; the placebo is the transdermal patch; the progesterone is compounded progesterone-100 mg
Study: NCT03888404

Intervention type: OTHER
Intervention: Pregnancy preferences (Aim 3a)
Description: The primary exposure of interest for Aim 3a will be pregnancy preferences, measured with the Desire to Avoid Pregnancy scale.

Intervention type: OTHER
Intervention: Pregnancy (Aim 3b)
Description: The exposure of interest for Aim 3b will be experiencing pregnancy. DAP level will be examined as an effect modifier.
Study: NCT00864214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bioidentical hormone (Biest)
Description: Estrogen is the Biest 2.5 mg bioidentical cream; the placebo is the transdermal patch; the progesterone is compounded progesterone-100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bioidentical hormone (Biest)
Description: Estrogen is the Biest 3.0 mg bioidentical cream; the placebo is the transdermal patch; the progesterone is compounded progesterone-100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bioidentical hormone (Vivelle-Dot)
Description: Estrogen is the Vivelle-Dot patch 0.05 mg; the placebo is the transdermal cream; the progesterone is micronized progesterone-100 mg
Study: NCT02994979

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Delirium-prevention
Description: Patients will be seen by an intervention CNA at least once daily 7 days a week. The CNA will be English/Spanish bilingual and will provide intervention components guided by structured protocols and a daily visit form. A typical visit lasts 30 minutes and begins with an introduction and orientation activity followed by provision of water, a reminiscence activity or game, a physical exercise, and a snack and second cup of water. Patients may also receive a relaxation visit at night and given a warm drink, a hand or foot massage, and quiet music. Daily visits will last for the duration of the illness and 7 days following the illness end. Illness end is defined as the last day of illness treatment (e.g., last day of antibiotics) or monitoring (e.g., last day on nursing 24-hour report). During weekly intervention staff meetings patients will be discussed with the primary medical and nursing team. The planned intervention group sample size results in a case load of 4-8 patients.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham comparator
Description: Usual care plus sham visits by CNA
Study: NCT00989378

Intervention type: BEHAVIORAL
Intervention: baseline study
Description: normal bedtimes
Study: NCT06220682

Intervention type: DIAGNOSTIC_TEST
Intervention: The specific genetic PCR laboratory test were performed for all selected patients for eNOS SNPs
Description: using Real-Time PCR (QuantStudioTM 3 Real-Time PCR) with an allele-specific fluorogenic oligonucleotide probe and a TaqMan pre-designed SNP Genotyping assay

Intervention type: DIAGNOSTIC_TEST
Intervention: The specific genetic PCR laboratory test were performed for all selected patients for eNOS SNPs
Description: using Real-Time PCR (QuantStudioTM 3 Real-Time PCR) with an allele-specific fluorogenic oligonucleotide probe and a TaqMan pre-designed SNP Genotyping assay
Study: NCT02241174

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Hypochlorite
Description: The 0.005% sodium hypochlorite solutions will be prepared from the commercially available Clorox® at 6% solution. 0.83ml of the 6% sodium hypochlorite solution will be taken and incorporated to a-100ml absolute distilled water. This 100ml solution will be stored in an amber glass bottle at room temperature unexposed to light at a maximum of 23 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Hypochlorite
Description: The 0.005% sodium hypochlorite solutions will be prepared from the commercially available Clorox® at 6% solution. 0.83ml of the 6% sodium hypochlorite solution will be taken and incorporated to a-100ml absolute distilled water. This 100ml solution will be stored in an amber glass bottle at room temperature unexposed to light at a maximum of 23 months